SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-22-008240
Filing Date
2022-08-01
Accepted
2022-08-01 06:10:30
Documents
13
Period of Report
2022-07-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_072922.htm   iXBRL 8-K 31412
2 PRESS RELEASE ex99-1.htm EX-99.1 12507
  Complete submission text file 0001387131-22-008240.txt   222394

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20220729.xsd EX-101.SCH 2998
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20220729_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20220729_pre.xml EX-101.PRE 22385
7 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_072922_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 221122673
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences